REPORT OF THE DIRECTORS AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2017
FOR
ECOSSE PHARMACEUTICALS LIMITED



CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2017

	Page
Company Information	1
Report of the Directors	2
Balance Sheet and Income Statement	3
Notes to the Financial Statements	4



ECOSSE PHARMACEUTICALS LIMITED

COMPANY INFORMATION FOR THE YEAR ENDED 31 MARCH 2017

DIRECTORS: J Cochrane Mrs S Gorrell

REGISTERED OFFICE: 3 Young Place

3 Young Place Kelvin Industrial Estate East Kilbride

East Kilbric Glasgow G75 0TD

REGISTERED NUMBER: SC210897 (Scotland)

REPORT OF THE DIRECTORS FOR THE YEAR ENDED 31 MARCH 2017

The directors present their report with the financial statements of the company for the year ended 31 March 2017.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 April 2016 to the date of this report.

J Cochrane Mrs S Gorrell

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

J Cochrane - Director

19 November 2017

BALANCE SHEET 31 MARCH 2017

TOTAL ASSETS LESS CURRENT	2017	2016
LIABILITIES	<u>£</u>	£
CAPITAL AND RESERVES Called up share capital Retained earnings SHAREHOLDERS' FUNDS	2 (2)	2 (2)

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the year ended 31 March 2017.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2017 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

ensuring that the company keeps accounting records which comply with Sections 386 and

(a) 387 of the Companies

Act 2006 and

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of

each financial year and of its profit or loss for each financial year in accordance with the

(b) requirements of Sections

394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial

statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the Board of Directors on 19 November 2017 and were signed on its behalf by:

J Cochrane - Director

INCOME STATEMENT FOR THE YEAR ENDED 31 MARCH 2017

During the financial year and the preceding financial year the company has not traded and has received no income and incurred no expenditure. Consequently, during those periods the company has made neither a profit nor a loss.

Downloaded from Datalog http://www.datalog.co.uk

The notes form part of these financial statements

Page 3

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2017

1. STATUTORY INFORMATION

Ecosse Pharmaceuticals Limited is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

3. ULTIMATE CONTROLLING PARTY

The ultimate controlling party is Munro Healthcare Group Limited.

